NHS to pay 25% more for innovative drugs after UK–US zero-tariff deal

• The UK has agreed to a deal with the US that will result in the NHS paying 25% more for innovative drugs by 2035, potentially costing an additional £3 billion annually. This agreement will also increase the percentage of GDP allocated by the NHS for such medicines from 0.3% to 0.6% over the next decade.
• This development signifies a substantial financial burden on the NHS, which currently spends £14.4 billion a year on innovative therapies, raising concerns about the sustainability of healthcare funding in the UK amidst rising drug costs.

— via World Pulse Now AI Editorial System